Literature DB >> 17176082

Alpha-synuclein adopts an alpha-helical conformation in the presence of polyunsaturated fatty acids to hinder micelle formation.

Kerensa Broersen1, Daan van den Brink, Graham Fraser, Michel Goedert, Bazbek Davletov.   

Abstract

Alpha-synuclein is a small cytosolic protein involved in the pathogenesis of Parkinson's disease and other neurodegenerative disorders. Recent studies suggested a lipid-related function for this brain-enriched protein. Since the brain carries a high level of docosahexaenoic acid (DHA) and since the extent of alpha-synuclein gene expression increases in response to DHA intake, we have investigated the interaction of alpha-synuclein with this essential omega-3 fatty acid. We show that alpha-synuclein allows DHA to be present in a soluble rather than micellar form. Upon interaction with DHA, the normally unstructured alpha-synuclein rapidly adopts an alpha-helical conformation. Prolonged exposure to DHA, however, gradually converts alpha-synuclein into amyloid-like fibrils. These results identify a potential biological function for alpha-synuclein and define an omega-3-linked pathway leading to alpha-synuclein aggregation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17176082     DOI: 10.1021/bi061743l

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  34 in total

Review 1.  The role of lipids in α-synuclein misfolding and neurotoxicity.

Authors:  Cathryn L Ugalde; Victoria A Lawson; David I Finkelstein; Andrew F Hill
Journal:  J Biol Chem       Date:  2019-05-07       Impact factor: 5.157

2.  Alpha-synuclein sequesters arachidonic acid to modulate SNARE-mediated exocytosis.

Authors:  Frédéric Darios; Violeta Ruipérez; Inmaculada López; Jose Villanueva; Luis M Gutierrez; Bazbek Davletov
Journal:  EMBO Rep       Date:  2010-05-21       Impact factor: 8.807

3.  Α-synuclein neuropathology is controlled by nuclear hormone receptors and enhanced by docosahexaenoic acid in a mouse model for Parkinson's disease.

Authors:  Eugenia Yakunin; Virginie Loeb; Haya Kisos; Yoav Biala; Shlomo Yehuda; Yoel Yaari; Dennis J Selkoe; Ronit Sharon
Journal:  Brain Pathol       Date:  2011-10-31       Impact factor: 6.508

4.  Probing the micelle-bound aggregation-prone state of α-synuclein with (19)F NMR spectroscopy.

Authors:  Gui-Fang Wang; Conggang Li; Gary J Pielak
Journal:  Chembiochem       Date:  2010-09-24       Impact factor: 3.164

5.  Identification of a helical intermediate in trifluoroethanol-induced alpha-synuclein aggregation.

Authors:  Valerie L Anderson; Trudy F Ramlall; Carla C Rospigliosi; Watt W Webb; David Eliezer
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-14       Impact factor: 11.205

6.  αS Oligomers Generated from Interactions with a Polyunsaturated Fatty Acid and a Dopamine Metabolite Differentially Interact with Aβ to Enhance Neurotoxicity.

Authors:  Shailendra Dhakal; Jhinuk Saha; Courtney E Wyant; Vijayaraghavan Rangachari
Journal:  ACS Chem Neurosci       Date:  2021-10-19       Impact factor: 4.418

7.  Binding of alpha-synuclein with Fe(III) and with Fe(II) and biological implications of the resultant complexes.

Authors:  Yong Peng; Chengshan Wang; Howard H Xu; You-Nian Liu; Feimeng Zhou
Journal:  J Inorg Biochem       Date:  2009-11-18       Impact factor: 4.155

8.  Catalytic function of PLA2G6 is impaired by mutations associated with infantile neuroaxonal dystrophy but not dystonia-parkinsonism.

Authors:  Laura A Engel; Zheng Jing; Daniel E O'Brien; Mengyang Sun; Paul T Kotzbauer
Journal:  PLoS One       Date:  2010-09-23       Impact factor: 3.240

9.  The influence of vesicle size and composition on alpha-synuclein structure and stability.

Authors:  Lars Kjaer; Lise Giehm; Thomas Heimburg; Daniel Otzen
Journal:  Biophys J       Date:  2009-04-08       Impact factor: 4.033

10.  Drug Targeting of alpha-Synuclein Oligomerization in Synucleinopathies.

Authors:  Tiago Fleming Outeiro; Aleksey Kazantsev
Journal:  Perspect Medicin Chem       Date:  2008-04-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.